Specialized cells at the leading edge of growing skin cancers dampen immune response and promote cancer invasion, Stanford researchers find. Targeting these cells could lead to effective therapies.
June 23, 2020 - By Krista Conger
An elite population of cancer cells marshal at the leading edges of a growing skin tumor to guide its metastasis and help it evade the body’s immune system, researchers at the Stanford University School of Medicine have found.
They do so by communicating not just with other cancer cells — goading them to divide and spread — but also with surrounding normal cells, recruiting specialized cells that dampen the immune response and others that promote cancer invasion.
“These cells coordinate the entire cancer process,” said Paul Khavari, MD, PhD, professor and chair of dermatology and the Carl J. Herzog Professor in Dermatology in the School of Medicine. “They are highly mobile and highly invasive, and they gather at the edges of the tumor to lead the charge into surrounding tissue. But until now, we didn’t even know they existed.”
Blocking these cancer masterminds’ communication abilities significantly slowed the growth of human tumor cells transplanted into laboratory mice, suggesting that similar targeted therapies may one day be successful in human cancers.
A paper describing the research was published online June 23 in Cell. Khavari is the senior author. Postdoctoral scholar and clinical instructor Andrew Ji, MD; former graduate student Adam Rubin, PhD; postdoctoral scholar Sizun Jiang, PhD; and Kim Thrane, a graduate student at the KTH Royal Institute of Technology in Sweden, share lead authorship of the study.
Common skin cancer
For the study, the researchers focused on a common skin cancer called squamous cell carcinoma, which affects more than 1 million people each year in the United States. Although most people are treated successfully, about 1% will eventually die from the disease. Squamous cell carcinoma belongs to a class of cancers known as epithelial cancers, which includes about 90% of all human cancer types.
To understand more about how epithelial cancers grow and metastasize, Khavari and his colleagues combined several techniques to analyze the architecture, cell types and gene expression profiles at the single-cell level of squamous cell carcinomas from 10 people — in effect, not just generating a molecular fingerprint for each cell but also precisely locating it and its neighbors within the three-dimensional space of the growing tumor.
“This told us the whole cast of players — who is where, what they are doing and who they are talking with,” Khavari said. “No one has ever looked at individual cells in concert with where they are and how they are arranged in space.”
They then compared their findings with normal skin from the same people whom the cancers were collected from. The findings are the first time such a comprehensive, integrated analysis has been conducted at the level of single cells, and it gives a never-before-seen glimpse into the cellular interactions both inside and outside the tumor.
The researchers found that the carcinomas differed from normal skin in their types of cells in one main way: In addition to mirroring the normal cell types, they had an additional subpopulation of cells Khavari and his colleagues called tumor-specific keratinocytes, or TSKs. Intriguingly, these TSKs were found primarily at the leading edges of the growing tumor, and they expressed genes that recruit specific cell types to the cancer site.
Some of the recruited cells are regulatory T-cells, or Tregs, which dampen the body’s natural immune response to prevent overreactions that can lead to autoimmune disorders. Others are cells called cancer-associated fibroblasts, which destabilize the extracellular matrix around the tumor and promote metastasis. Still others are endothelial cells, which line the interior of blood and lymph vessels.
‘Paving the way for invasion’
“These TSKs are leading the charge from a special niche environment at the edge of the tumor,” Khavari said. “There they can talk not only to the other cancer cells, but also to cells in the surrounding environment, paving the way for cancerous invasion into surrounding tissue. When we knocked out the ability of these cells to communicate, we stopped the growth of human squamous cell carcinomas that had been transplanted into mice.”
The researchers are now investigating whether their findings extend beyond squamous cell carcinomas.
“Are these tumor-specific cells a feature of most or all epithelial cancers?” Khavari said. “We’re not sure, but we can see that people whose cancers expressed high levels of genes associated with these cells had poorer outcomes.”
The researchers also are interested in learning how to use what they’ve learned in the study to create new, targeted therapies.
“Cancer really remodels the immune system to shut it down,” Khavari said. “Our study shows that the TSKs recruit Tregs, which form a barrier between the tumor and the surrounding tissue and create an immune-suppressed environment. It’s becoming obvious that successful cancer therapies will have to not just attack the tumor cells, but also find a way to activate the immune system and get it to stop tolerating the cancer.”
Other Stanford co-authors of the study are postdoctoral scholars David Reynolds, PhD, Jordan Meyers, PhD, and Xavier Rovira Clavé, PhD; graduate students Robin Meyers, Margaret Guo, Yunhao Bai and Bokai Zhu; former graduate student Benson George, MD, PhD; former clinical associate professor of dermatology S. Tyler Hollmig, MD; professor of dermatology Sumaira Aasi, MD; and Garry Nolan, PhD, professor of pathology and the Rachford and Carlota A. Harris Professor.
Researchers from Sweden’s KTH Royal Institute of Technology and the University of California, San Francisco, also contributed to the study.
About Stanford Medicine
Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients. For more information, please visit med.stanford.edu.